U.S. MarketsJuly 23 at 06:36 AM

Eli Lilly (LLY) is preparing Retatrutide applications after positive weight loss data, WSJ reports

StockNow breaking-news AI analysis

Eli Lilly is preparing 2026 regulatory filings for Retatrutide after data showed 28% weight loss. Despite a lawsuit from Novo Nordisk, analysts remain bullish with a $1,270 target for LLY.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLY Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy